1 |
Cao Y, Tan A, Gao F, et al (2009). A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis, 24, 677-85.
DOI
|
2 |
Choi KH, Park SM, Lee K, et al (2013). Prevalence, awareness, control, and treatment of hypertension and diabetes in Korean cancer survivors: a cross-sectional analysis of the fourth and fifth Korea national health and nutrition examination surveys. Asian Pac J Cancer Prev, 14, 7685-92.
과학기술학회마을
DOI
|
3 |
Daher IN, Yeh ET (2008). Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med, 5, 797-805.
DOI
|
4 |
Havlik RJ, Yancik R, Long S, Ries L, Edwards B (1994). The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74, 2101-6.
DOI
ScienceOn
|
5 |
Izzedine H, Ederhy S, Goldwasser F, et al (2009). Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol, 20, 807-15.
DOI
ScienceOn
|
6 |
Jain M, Townsend RR (2007). Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep, 9, 320-8.
DOI
ScienceOn
|
7 |
Janssen-Heijnen MLG, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JWW (1998). Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer, 21, 105-13.
DOI
ScienceOn
|
8 |
Janssen-Heijnen MLG, Smulders S, Lemmens VEPP, et al (2004). Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax, 59, 602-7.
DOI
|
9 |
Ko C, Chaudhry S (2002). The need for a multidisciplinary approach to cancer care. J Surg Res, 105, 53-7.
DOI
ScienceOn
|
10 |
Lopez-Encuentra A (2002). Comorbidity in operable lung cancer: a multicenter descriptive study on 2992 patients. Lung Cancer, 35, 263-9.
DOI
|
11 |
Pereira A, Garmendia ML, Alvarado ME, Albala C (2012). Hypertension and the risk of breast cancer in Chilean women: a case-control study. Asian Pac J Cancer Prev, 13, 5829-34.
과학기술학회마을
DOI
|
12 |
Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL., Jr (2004). Prognostic importance of comorbidity in a hospitalbased cancer registry. JAMA, 291 2441-7.
DOI
|
13 |
Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010). Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens, 23, 460-8.
DOI
ScienceOn
|
14 |
Satariano WA, Ragland DR (1994). The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med, 120, 104-10.
DOI
ScienceOn
|
15 |
Smith AW, Reeve BB, Bellizzi KM, et al (2008). Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev, 29, 41-56.
|
16 |
Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005). Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 294, 1765-72.
DOI
ScienceOn
|
17 |
Townsend RR (2006). Hypertension and cancer chemotherapies. In: Mohler ER, Townsend RR, editors. Advanced Therapy in Hypertension and Vascular Disease. Toronto, Canada: BC Decker; 2006. pp. 502-7.
|
18 |
Yeh ETH (2006). Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med, 57, 485-98.
DOI
|
19 |
Yancik R, Wesley MN, Ries LA, et al (1998). Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer, 82, 2123-34.
DOI
ScienceOn
|
20 |
Yancik R, Wesley MN, Ries LAG, et al (2001). Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 285, 885-92.
DOI
ScienceOn
|